![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
A more recent version of this article appeared on June 1, 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 1, 2005
Revised on March 16, 2006
Accepted on March 22, 2006
School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney 2052, Australia
Monitoring Editor: Ben Margolis
Akt is a critical regulator of cell growth, proliferation and survival that is activated by phosphatidylinositol 3-kinase (PI3K). We investigated the effect of PI3K inhibition on activation of sterol regulatory element binding protein-2 (SREBP-2), a master regulator of cholesterol homeostasis. SREBP-2 processing increased in response to various cholesterol depletion approaches (including statin treatment) and this increase was blunted by treatment with a potent and specific inhibitor of PI3K, LY294002, or when a plasmid encoding a dominant-negative form of Akt (DN-Akt) was expressed. LY294002 also suppressed SREBP-2 processing induced by insulin-like growth factor-1. Furthermore, LY294002 treatment down-regulated SREBP-2 or -1c gene targets, and decreased cholesterol and fatty acid synthesis. Fluorescence microscopy studies indicated that LY294002 disrupts transport of the SREBP escort protein, SCAP, from the endoplasmic reticulum to the Golgi. This disruption was also shown by immunofluorescence staining when DN-Akt was expressed. Taken together, our studies indicate that the PI3K/Akt pathway is involved in SREBP-2 transport to the Golgi, contributing to the control of SREBP-2 activation. Our results provide a crucial mechanistic link between the SREBP and PI3K/Akt pathways which may be reconciled teleologically since synthesis of new membrane is an absolute requirement for cell growth and proliferation.
This article has been cited by other articles:
|
|
 |
|
  S. A. Siddiqi and C. M. Mansbach II PKC{zeta}-mediated phosphorylation controls budding of the pre-chylomicron transport vesicle J. Cell Sci., July 15, 2008; 121(14): 2327 - 2338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Morin, L. A. Nichols, K. M. Zalasky, J. W. Davis, J. A. Manthey, and L. J. Holland The Citrus Flavonoids Hesperetin and Nobiletin Differentially Regulate Low Density Lipoprotein Receptor Gene Transcription in HepG2 Liver Cells J. Nutr., July 1, 2008; 138(7): 1274 - 1281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Mahoney, A. Safdar, G. Parise, S. Melov, M. Fu, L. MacNeil, J. Kaczor, E. T. Payne, and M. A. Tarnopolsky Gene expression profiling in human skeletal muscle during recovery from eccentric exercise Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2008; 294(6): R1901 - R1910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Matsuzaki, V. Besnard, J. C. Clark, Y. Xu, S. E. Wert, M. Ikegami, and J. A. Whitsett STAT3 Regulates ABCA3 Expression and Influences Lamellar Body Formation in Alveolar Type II Cells Am. J. Respir. Cell Mol. Biol., May 1, 2008; 38(5): 551 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Horvath, L. Tackett, A. M. McCarthy, P. Raman, J. T. Brozinick, and J. S. Elmendorf Antidiabetogenic Effects of Chromium Mitigate Hyperinsulinemia-Induced Cellular Insulin Resistance via Correction of Plasma Membrane Cholesterol Imbalance Mol. Endocrinol., April 1, 2008; 22(4): 937 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pertusa, C. Morenilla-Palao, C. Carteron, F. Viana, and H. Cabedo Transcriptional Control of Cholesterol Biosynthesis in Schwann Cells by Axonal Neuregulin 1 J. Biol. Chem., September 28, 2007; 282(39): 28768 - 28778. [Abstract] [Full Text] [PDF]
|
|
